GSK plc (GSK)
| Market Cap | 100.70B +24.2% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.13 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 15.74 |
| Forward PE | 9.95 |
| Dividend | $1.79 (3.52%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,432,149 |
| Open | 50.22 |
| Previous Close | 50.27 |
| Day's Range | 49.95 - 50.88 |
| 52-Week Range | 38.63 - 61.70 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 58.58 (+15.27%) |
| Earnings Date | Jul 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $58.58, which is an increase of 15.27% from the latest price.
News
Noetik Achieves First Milestone in Landmark GSK Collaboration
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--Noetik achieves first milestone in landmark GSK collaboration.
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy
GSK said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S. regulatory review as a possible rectal ...
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scie...
GSK India first-quarter profit rises on steady vaccine demand
Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable demand across its vaccine and drug portfolio, including respiratory and special...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train AI models ...
GSK plc Earnings Call Transcript: Q2 2026
Q2 saw 5% sales growth and strong cash generation, led by specialty medicines and vaccines. The Accelerate Growth program targets £1.9B in annual savings to fund R&D and protect margins through key LOE periods, while the Nuvalent acquisition expands the oncology pipeline.
GSK plc Quarterly report: Q2 2026
GSK plc has published its Q2 2026 quarterly earnings report on July 28, 2026.
GSK plc Slides: Q2 2026
GSK plc has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company's 2031 sales target.
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
GSK on Tuesday beat second-quarter profit expectations and launched a £1.9 billion ($2.52 billion) cost savings drive as the British drugmaker seeks to ramp up its development pipeline to sup...
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 years in the country, including a new R&D center in Cambridge as part of its plans to develop medicine...
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goal of keeping an aggressive bone cancer from worsening in a late-stage trial, just weeks after ...
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy a...
US FDA approves GSK's lung cancer drug
GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its int...
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
GSK to halt further development of cough drug after missing main goal
GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after...
GSK's targeted cancer therapy shows positive results in late-stage study
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant...
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...